BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CELLMED Research GmbH Release: First Clinical Data on the Safety of PROCURE® During Trial Phase I/IIa


12/13/2011 9:57:06 AM

December 13, 2011 -- On December 12th 2011 Life Research Technologies GmbH, the clinical subsidiary of CELLMED and sponsor of the phase I/IIa trial of PROCURE® in ovarian cancer, received a positive ruling on the interim safety report of PROCURE® from the ethics committee.

PROCURE® is CELLMED’s lead product, a patented innovative immunotherapy for the treatment of ovarian cancer and other solid tumors. Using a unique double loading of dendritic cells with the universal tumor antigens Survivin and TERT the goal of the treatment with PROCURE® is to delay or ultimately prevent tumor recurrence. Two patients have successfully received all eight vaccines. As stipulated by the ethics committee, following the second vaccination of the third patient all side effects recorded so far were discussed by the Data Safety Management Board with its chairman Univ.-Prof. Dr. Michael Krainer. As no safety risk whatsoever was found, it was recommended to continue the clinical trial without any objections. After a further appraisal of the interim report by the review board of the ethics committee they ruled in favour of continuing the study.

“We are very pleased that all our vaccinated patients are doing well and that the hoped for reactions such as fever and skin redness were present in all three patients within days of vaccination. These reactions are indicators of a successful stimulation of the immune system”, says Prim.

Univ.-Doz. Dr. Martin Imhof, the medical supervisor of the clinical trial phase I/IIa. “With this positive intermediate result we have taken an important hurdle on the path to success for the treatment of ovarian cancer with our vaccine PROCURE®. We are highly motivated to plan our further clinical development program. We expect to complete the recruitment for phase I/IIa by the summer of 2012 and plan to begin with trial phase IIb of our study by late 2012” adds Dr. Karl Krista, who, as of November 23rd 2011, heads the CELLMED as Chief Executive Officer.

“A financing round of EUR 17.8m is needed to fund the company until the completion of results for phase IIb in the year 2015.”

About CELLMED Research GmbH

CELLMED Research GmbH, together with its subsidiaries “Life Research Technologies GmbH” and “Cellpro Danube GmbH”, constitutes an Austrian life science group founded in 2006. Its main focus is on the development and legal approval of its lead product PROCURE®, a patented autologous cellular immunotherapy for the treatment of ovarian cancer and other solid tumors. The uniqueness of PROCURE® is based on the double loading of dendritic cells with the universal tumor antigens Survivin and TERT. This is expected to lead to an increased immune response. The goal of the treatment with PROCURE® is to delay or ultimately prevent tumor recurrence. CELLMED Research GmbH Dr. Karl Krista CEO karl.krista@cellmed.at www.cellmed.at Magnesitstraße 1 3502 Krems-Lerchenfeld Austria T +43 2732 70 51 20



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES